Business Description
Xenon Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA98420N1050
Total Employee Number:
370Description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 146.14 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.2 | |||||
3-Year EBITDA Growth Rate | -30.4 | |||||
3-Year EPS without NRI Growth Rate | -29.8 | |||||
3-Year FCF Growth Rate | -27.2 | |||||
3-Year Book Growth Rate | -14.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 272.17 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.8 | |||||
9-Day RSI | 80.15 | |||||
14-Day RSI | 74.15 | |||||
3-1 Month Momentum % | -6.97 | |||||
6-1 Month Momentum % | 28.98 | |||||
12-1 Month Momentum % | 63.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 27.79 | |||||
Quick Ratio | 27.79 | |||||
Cash Ratio | 27.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.5 | |||||
Shareholder Yield % | -14.29 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -4122.81 | |||||
OCF Margin % | -4110.91 | |||||
ROE % | -50.19 | |||||
ROA % | -47.36 | |||||
ROIC % | -231.58 | |||||
3-Year ROIIC % | 340.43 | |||||
ROC (Joel Greenblatt) % | -2592.61 | |||||
ROCE % | -53.45 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 637.26 | |||||
PB Ratio | 4.37 | |||||
Price-to-Tangible-Book | 4.37 | |||||
EV-to-EBIT | -11.55 | |||||
EV-to-EBITDA | -11.62 | |||||
EV-to-Revenue | 635.32 | |||||
EV-to-Forward-Revenue | 421.41 | |||||
EV-to-FCF | -15.51 | |||||
| Price-to-Net-Current-Asset-Value | 5.53 | |||||
| Price-to-Net-Cash | 5.6 | |||||
Earnings Yield (Greenblatt) % | -8.66 | |||||
FCF Yield % | -5.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xenon Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.405 | ||
| EPS (TTM) (€) | -4.039 | ||
| Beta | 0.0282 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 0.79 | ||
| Volatility % | 36.73 | ||
| 14-Day RSI | 74.15 | ||
| 14-Day ATR (€) | 0.696954 | ||
| 20-Day SMA (€) | 47.975 | ||
| 12-1 Month Momentum % | 63.31 | ||
| 52-Week Range (€) | 25.6 - 53.5 | ||
| Shares Outstanding (Mil) | 96.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xenon Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xenon Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 16:30 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 35 days | ||
| Jeffries Global Healthcare Conference | 2026-06-04 09:55 | 44.60 (+0.00%) | ||
| General meeting for 2026 | 2026-06-02 09:30 | 46.60 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 48.80 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 48.80 (+0.00%) | ||
| Bloom Burton & Co. Healthcare Investor Conference | 2026-04-22 11:30 | 48.00 (+0.00%) | ||
| Phase 3 X-TOLE2 Study Topline Results | 2026-03-09 08:00 | 36.20 (+0.00%) |
Show
Entries
Xenon Pharmaceuticals Inc Frequently Asked Questions
What is Xenon Pharmaceuticals Inc(FRA:XP0)'s stock price today?
The current price of FRA:XP0 is €53.00. The 52 week high of FRA:XP0 is €53.50 and 52 week low is €25.60.
When is next earnings date of Xenon Pharmaceuticals Inc(FRA:XP0)?
The next earnings date of Xenon Pharmaceuticals Inc(FRA:XP0) is 2026-08-11 Est..
Does Xenon Pharmaceuticals Inc(FRA:XP0) pay dividends? If so, how much?
Xenon Pharmaceuticals Inc(FRA:XP0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Xenon Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers